Identification of a novel SEREX antigen family, ECSA, in esophageal squamous cell carcinoma

Akiko Kagaya1,2†, Hideaki Shimada3†, Tooru Shiratori2, Mari Kuboshima1,2, Kazue Nakashima-Fujita1,2, Mari Yasuraoka1, Takanori Nishimori2, Shunsuke Kurei3, Takahisa Hachiya4, Akihiro Murakami4, Yutaka Tamura5, Fumio Nomura6, Takenori Ochiai7, Hisahiro Matsubara2, Masaki Takiguchi1 and Takaki Hiwasa1*

Abstract

Background: Diagnosis of esophageal squamous cell carcinoma (SCC) may improve with early diagnosis. Currently it is difficult to diagnose SCC in the early stage because there is a limited number of tumor markers available.

Results: Fifty-two esophageal SCC SEREX antigens were identified by SEREX (serological identification of antigens by recombinant cDNA expression cloning) using a cDNA phage library and sera of patients with esophageal SCC. Sequence analysis revealed that three of these antigens were similar in amino acid sequences, and they were designated as ECSA (esophageal carcinoma SEREX antigen)-1, -2 and -3. The ECSA family was also similar to an EST clone, hepatocellular carcinoma-associated antigen 25a (HCA25a). Serum antibody levels to ECSA-1, -2 and -3 were significantly higher in patients with esophageal SCC than in healthy donors. Based on the conserved amino acid sequences, three peptides were synthesized and used for enzyme-linked immunosorbent assays (ELISA). The serum antibody levels against one of these peptides were significantly higher in patients with esophageal SCC. This peptide sequence was also conserved in FAM119A, GOSR1 and BB55, suggesting that these are also ECSA family members. Reverse transcription followed by quantitative PCR analysis showed that the mRNA expression levels of ECSA-1, -2 and -3 and FAM119A but not of HCA25a, GOSR1 and BB55 were frequently elevated in esophageal SCC tissues.

Conclusions: We have identified a new gene family designated ECSA. Serum antibodies against the conserved domain of the ECSA family may be a promising tumor marker for esophageal SCC.

Background

Esophageal squamous cell carcinoma (SCC) is one of the most malignant tumors. The 5-year survival rate varies between 20% and 40% [1-3]. Despite improvements in surgical techniques and adjuvant chemoradiotherapy, many patients suffer from rapid recurrence of the disease and have a poor prognosis [4]. Because these tumors are aggressive, patients often present with systemic involvement due to delayed diagnosis [3]. Although several tumor markers have been identified in esophageal SCC, they are not sufficiently prevalent to allow for use as a general diagnostic tool [5-7].

It has been known for several decades that the immune system is able to recognize tumor cells [8,9], and by testing for autoimmunity against tumor-associated antigens it is possible to identify tumor markers. This analytical method developed by Sahin et al. is called SEREX (serological identification of antigens by recombinant cDNA expression cloning) [10]; it involves immunoscreening with autologous or allogeneic sera of expressed cDNA libraries prepared from tumor specimens. Since the antigens are easily identified by sequencing the isolated cDNA clones, SEREX is suitable for large-scale screening of tumor antigens. SEREX has been applied to a variety of human tumor types and has successfully identified over 1,000 novel tumor antigens [11].

The SEREX method has been applied to esophageal SCC and has also identified NY-ESO-1, a gene product of testicular cells. This antigen is overexpressed in various types of cancer cells [12]. SEREX analysis has also led to the isolation of several antigens known to be associated with malignancy, including a mutated version of p53 tumor suppressor protein in esophageal cancer.
The presence of serum p53 antibodies has been associated with poor prognosis [15].

In the previous series of SEREX screening in esophageal SCC, we identified several new SEREX antigens, including TROP2, SURF1, SLC2A1, TRIM21, myomegalin and makorin 1 [16-25]. In the present series, we have identified a novel gene family, designated ECSA (Esophageal Carcinoma SEREX Antigen), by SEREX screening and have evaluated the clinicopathological significance of serum ECSA antibodies (s-ECSA-Abs) in patients with esophageal SCC.

**Results**

**Serological screening of cDNA Library**

A phage expression library was constructed from the mRNA of an esophageal SCC cell line, T.Tn. A total of 3 × 10⁶ clones of cDNA were screened using sera from three patients with esophageal SCC, and 52 reactive clones were isolated. DNA sequence analysis and homology search, using the National Center for Biotechnology Information (NCBI) databases, revealed that the DNA sequences of three clones, 10Q3-1, 12N1-1 and 12O1-1, were similar but not identical. Almost identical sequences of 10Q3-1, 12N1-1 and 12O1-1 were found on chromosomes X, 9 and 19, respectively, suggesting that these three clones were independent. Thus, these genes belonged to a novel gene family, designated as the ECSA (esophageal carcinoma SEREX antigen) family. Clones 10Q3-1, 12N1-1 and 12O1-1 were designated as ECSA-1, -2 and -3, respectively. These genes were also similar to an EST clone, hepatocellular carcinoma-associated antigen (HCA25a) (Accession number: AF469043). The coding sequences of ECSA-1, -2 and -3 are not known yet; their putative amino acid sequences are shown in Additional File 1. Nucleotide and amino acid sequence homologies among these genes are shown in Tables 1 and 2. ECSA-1 and HCA25a were 91.6% homologous in the nucleotide sequences and 86.8% homologous in the amino acid sequences. The amino-terminal region of ECSA-1 was homologous not only to HCA25a amino acids 53 through 117 but also to HCA25a amino acids 2 through 41 (Figure 1), indicating that HCA25a contains internal repetitive sequences. ECSA family sequences are highly conserved, especially in repetitive regions.

| Table 1 Nucleotide sequence homology among ECSA family members and HCA25a |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                             | ECSA-1 | ECSA-2 | ECSA-3 | HCA25a |
| ECSA-1                      | 100.0  | 87.0   | 70.0   | 91.6   |
| ECSA-2                      | 87.0   | 100.0  | 79.3   | 84.8   |
| ECSA-3                      | 70.0   | 79.3   | 100.0  | 73.0   |
| HCA25a                      | 91.6   | 84.8   | 73.0   | 100.0  |

Percent homologies of nucleotide sequences are shown.

**Presence of serum ECSA antibodies (s-ECSA-Abs) in patients with esophageal SCC**

To confirm the presence of s-ECSA-Abs in patients with esophageal SCC, Western blotting was performed using bacterially expressed ECSA gene products as described previously [16-19]. Figure 2 shows representative positive and negative results for s-ECSA-2-Abs. Only signals that appeared in the samples pretreated with IPTG were judged as sero-positive. The size of the IPTG-dependent polypeptide was approximately 15 kDa, which was consistent with the estimated size of the fusion protein of pBluescript II-encoded β-Gal and the amino-terminal truncated ECSA-2 protein. The results shown in Figure 1 indicate that the serum of patient-1 (P#1) was seronegative for s-ECSA-2-Abs, while the serum of patient-2 (P#2) was sero-positive. We examined the sero-positivity for s-ECSA-2-Abs in sera from 40 patients with esophageal SCC and 20 healthy donors. Positive reactions were detected in sera of 40% (16 of 40) of patients, whereas the sero-positivity for s-ECSA-2-Abs in healthy donors was only 10% (2 of 20).

**ELISA assay to detect serum antibodies**

Although it is possible to evaluate the presence or absence of serum antibodies by Western blotting, only a limited quantitative estimation is possible. ELISA assays were performed on sera from patients and healthy donors using a recombinant antigen protein to analyze the levels of s-ECSA-Abs quantitatively. cDNA of ECSA-2 was recombined into pGEX-4T, which produced the GST-ECSA-2 fusion protein after treatment with IPTG. The fusion protein was affinity-purified by glutathione-Sepharose (Additional File 2). The levels of serum antibody in patients with esophageal SCC were significantly higher than those in healthy donors (0.145 ± 0.483 versus 0.050 ± 0.087, P = 0.0026) (Figure 3). The levels of s-ECSA-2-Ab were divided into two groups: A serum level less than 0.31 was considered normal, as this was the mean + three standard deviations (SD) of s-ECSA-2-Ab level of healthy donors; abnormal or positive values were higher than 0.31. The positive rate of patients with esophageal SCC was higher than that of healthy donors (15.3% versus 1.0%). ELISA using purified recombinant ECSA-1 and -3 proteins revealed that serum antibody levels against ECSA-1 and -3 also were significantly higher in patients compared to healthy donors.
higher in patients with esophageal SCC than in healthy donors (Table 3).

Next, we evaluated the relationship between clinico-pathological parameters and the presence of s-ECSA-Abs. The survival of s-ECSA-Ab-negative patients was superior to that of s-ECSA-Ab-positive patients, although the differences were not statistically significant (P = 0.1851, Figure 4). There was no correlation between the presence of s-ECSA-Abs and other clinico-pathological variables such as gender, age, tumor location, tumor depth, N factor or M factor (Table 4). A multivariate analysis was also performed to evaluate the prognostic significance of s-ECSA-Abs. Although TNM factors were independent risk factors for survival, s-ECSA-Abs were not (data not shown).

ELISA assay using synthetic peptides
The isolated ECSA clones may not be full-length because they did not contain an initiation codon in the 5'-terminal region, and the putative open reading frame is short (Additional File 1). However, the results of
Western blotting (Figure 2) and ELISA (Figure 3) suggest that the epitope is located in the short and conserved region of the ECSA family peptides. Thus, we synthesized short peptides based on the repetitive sequences of HCA25a, and used them as antigens to examine the levels of serum antibodies and to characterize the peptide epitope. Three peptides, HCA-26/41, HCA-57/71 and HCA-81/97 were designed and used for ELISA (Figure 1). The serum antibody levels against HCA-81/97 were significantly higher in patients with esophageal SCC than in healthy donors (Figure 5, Table 3). Similar results were also observed against HCA-57/71, but the difference between patients and healthy donors was insignificant. The antibody levels against HCA-26/41 were very low in both patients and healthy donors. When the cut-off value was defined as the average + 3 SD, 22% of patients with esophageal SCC were positive for the serum anti-HCA-81/97 antibody but none of the healthy donors were positive (Table 3). To define the epitope site more precisely, the antibody response to other synthetic peptides, such as HCA-74/88, HCA-85/97 and HCA-88/97, was examined by ELISA. None of these peptides showed significant differences in the serum antibody levels between patients and healthy donors (Table 3), suggesting that an almost full-length sequence of HCA-81/97 is required to react with the serum antibodies.

Identification of other ECSA family members

Then we searched again with the amino acid sequence of HCA-81/97, NH2-ARPPLLGSEEPLCPASR-COOH, not only for the sequences in the coding region of cDNAs but also for the amino acid sequences deduced from sense or antisense nucleotide sequences of cDNAs. This search identified the following three genes: Family with sequence similarity 119, member A (FAM119A), golgi SNAP receptor complex member 1 (GOSR1) and Bardet-Biedl syndrome 5 (BBS5) (Figure 6). It is of considerable interest that the conserved sequences appeared repeatedly as observed in HCA25a. However, all of these repeated sequences were located in the 3'-untranslated region, and some were found in the antisense strands (in the opposite direction). It remains unknown whether

Table 3 Serum antibody levels against ECSA proteins or peptides examined by ELISA

|       | ECSA-1 | ECSA-2 | ECSA-3 | HCA-26/41 | HCA-57/71 | HCA-81/97 | HCA-74/88 | HCA-85/97 | HCA-88/97 |
|-------|--------|--------|--------|-----------|-----------|-----------|-----------|-----------|-----------|
|       | HD P   | HD P   | HD P   | HD P      | HD P      | HD P      | HD P      | HD P      | HD P      |
| Average| 0.004  | 0.132  | 0.050  | 0.145     | 0.011     | 0.230     | 0.009     | 0.010     | 0.025     |
| SD    | 0.387  | 0.087  | 0.483  | 0.087     | 0.066     | 0.037     | 0.015     | 0.071     | 0.160     |
| Positive (%) | 2/118 | 31/146 | 1/98   | 11/72     | 1/74      | 1/68      | 1/42      | 1/63      | 0/42      |
| P value (T-test) | 0.0001 | 0.0026 | 0.0079 | 0.8848    | 0.0702    | 0.0001    | 0.6690    | 0.8210    | 0.1738 |

Synthetic peptides used were: HCA-26/41, biotin-EGGGGVSPPPGQPPCP; HCA-57/71, biotin-SGREVGGSAPCPASR; HCA-81/97, biotin-ARPPLLGSEEPLCPASR; HCA-74/88, biotin-REVRGASARPPLLGS; HCA-85/97, biotin-PPLGSEEPLCPASR; and HCA-88/97, biotin-SEEPLCPASR. ECSA-1, 2 and 3 were GST-fusion proteins.

Figure 3 s-ECSA-2-Ab levels examined by ELISA. The levels of s-ECSA-2-Ab were measured by ELISA using purified GST-ECSA-2 protein and control GST protein. The box plots display the 25th, 50th, and 75th percentiles. The upper and lower cross bars of the box represent 90th and 10th percentiles, respectively. The position of a cut-off value (Average + 3 SD; 0.31) is shown. Values higher than 90th percentile are shown by dots.

Figure 4 Kaplan-Meier overall survival curves for the patients with and without s-ECSA-2-Ab. The P value calculated by the log-rank test was 0.1851.
these conserved sequences can be translated under certain conditions.

Expression of ECSA in esophageal SCC

The expression of the ECSA family members was examined by realtime RT-PCR, and the results showed that the mRNA expression levels of ECSA-1, -2 and -3 and FAM119A were elevated more frequently in tumor tissues than in the surrounding normal tissues (Figure 7a, b, c and 7e; Additional File 3). The elevation was most frequently seen for ECSA-2 (9 of 12 cases) and was most prominent for ECSA-3 (10 to 40-fold increase in tumor tissues). On the other hand, the expression levels of HCA25a and GOSR1 were relatively low and not apparently different between the tumor and normal tissues (Figure 7d and 7f). The expression of BBS5 was almost undetectable in all specimens (data not shown). Thus, it is possible that some, but not all, of the members of the ECSA family are involved in carcinogenesis of esophageal SCC.

Immunostaining of ECSA in esophageal carcinoma specimens

We then developed monoclonal antibodies against HCA25a protein and investigated the expression and distribution of ECSA protein by immunohistochemical analysis. Because this monoclonal antibody recognized not only HCA25a but also ECSA-1, -2 and -3 proteins, it was designated as pan-ECSA mAb. We used formalin-fixed esophageal tissue specimens that contained esophageal carcinoma and normal cells of s-ECSA-Abs-positive patients. A representative result (Figure 8) showed that esophageal SCC tissue was more heavily stained than normal esophageal tissue. ECSA proteins appeared to be more abundant in the cytoplasm than in the nucleus.

Discussion

SEREX screening has been performed in esophageal carcinomas by Chen et al. [12] and Tureci et al. [26], who successfully identified NY-ESO-I and NY-ESO-II. In the present study, we identified ECSA-1, -2 and -3 as new SEREX antigens of esophageal SCC. Recent studies have shown that serum autoantibodies such as p53 and AFP are useful tumor markers [13-15,27]. s-ECSA-Abs levels examined by ELISA were higher than the cut-off value in 15 - 21% of patients with esophageal SCC (Table 3). Although this rate was not higher than the positive rates of conventional tumor markers such as CYFRA 21-1, CEA and SCC-Ag (24 - 39%) [14], the positive rates of s-ECSA-Abs in healthy donors were less than 2%, indicating very low false-positive rates. Based on the amino acid sequences conserved among ECSA family members,

Table 4 Relationship between s-ECSA-2-Abs and the clinicopathological variables in patients with esophageal SCC

| Variables      | No. of patients with s-ECSA-2-Abs (positive rate %) | P-value |
|----------------|------------------------------------------------------|---------|
| Gender         |                                                      |         |
| Male (63)      | 10 (16)                                              | >0.9999 |
| Female (9)     | 1 (11)                                               |         |
| Age            |                                                      |         |
| <65 years (31) | 6 (19)                                               | 0.5132  |
| ≥65 years (41) | 5 (12)                                               |         |
| Tumor location |                                                      |         |
| Upper (13)     | 1 (8)                                                | 0.6757  |
| Lower (59)     | 10 (17)                                              |         |
| Tumor size     |                                                      |         |
| <50 mm (39)    | 4 (10)                                               | 0.3245  |
| ≥50 mm (33)    | 7 (21)                                               |         |
| Tumor depth    |                                                      |         |
| T1, T2 (35)    | 3 (9)                                                | 0.1906  |
| T3, T4 (37)    | 8 (22)                                               |         |
| N factor       |                                                      |         |
| N0 (25)        | 1 (4)                                                | 0.0836  |
| N1 (47)        | 10 (21)                                              |         |
| M factor       |                                                      |         |
| M0 (61)        | 8 (13)                                               | 0.3562  |
| M1 (11)        | 3 (27)                                               |         |
| Stage          |                                                      |         |
| I, II (37)     | 3 (8)                                                | 0.1073  |
| III, IV (35)   | 8 (35)                                               |         |

Figure 5 Serum antibody levels against the synthetic peptides, HCA-26/41, HCA-57/71 and HCA-81/97. The levels of serum antibodies against synthetic peptides in sera of patients with esophageal SCC (P) and healthy donors (HD) were examined by sandwich ELISA.
three peptides were synthesized and used for ELISA. One of these peptides, HCA-81/97, was detected with a sensitivity of 22% and a specificity of 100%. Such a high specificity suggests the usefulness of s-ECSA-Abs in the diagnosis of esophageal SCC.

Until we identified three ECSA family members, only one member, HCA25a, had been reported, but with no detailed information. However, three HCA25a-like genes of the chimpanzee have recently been registered in the NCBI database. Thus, the ECSA/HCA25a family may be conserved among primates. In addition to ECSA-1, -2 and -3, three members, FAM119A, GOSR1 and BBS5, were identified by a homology search (Figure 6). We designated this family as the ECSA (esophageal carcinoma SEREX antigen) family but did not include the HCA25a family name because HCA25a was not apparently related to esophageal SCC (Figure 7).

The mRNA expression levels of ECSA-1, -2 and -3 and FAM119A in tumor tissues were frequently higher than those in normal tissues (Figure 7). Consistently, immunohistochemical analysis using a pan-ECSA mAb showed that the expression levels of ECSA proteins were low in normal tissues but high in SCC (Figure 8). Such tumor-specific expression suggests that these ECSA family members may play a crucial role in carcinogenesis. However, none of the isolated ECSA clones (ECSA-1, -2 and -3) contained apparent initiation codons (Additional File 1), and the conserved sequence was identified frequently in the 3'-untranslated regions of the family members (Figure 6). It is plausible that they are expressed by alternative splicing under certain conditions in tumor cells. The development of serum autoantibodies against the conserved sequence of the ECSA family suggests that the conserved domain in some members of the ECSA family was translated into proteins. Nevertheless, it cannot be ruled out that ECSA RNA may not exert an effect through its peptide product but instead may act as antisense RNA or microRNA molecules [28]. Alternatively, the DNA region harboring the conserved ECSA sequence may be a binding site of chromatin modifiers such as histone acetyltransferase, and thereby, enhance gene expression.

TROP-2 [16], SURF1 [17], SLC2A1 [18], TRIM21 [19], myomegalin [21], UBE2I [22], AISEC [23], CUEC-23 [24] and makorin1 [25] are novel tumor marker SEREX antigens of esophageal SCC. Among these markers, ECSA has shown the highest specificity. Although the presence of s-ECSA-Abs was partly associated with a poor prognosis (Figure 4), further trial data might verify the validity of ECSA as a diagnostic marker.

We evaluated the clinical significance of s-ECSA-Abs in patients with esophageal SCC. The presence of s-ECSA-Abs was partly associated with a poor prognosis (Figure 4). The very low false-positive reactivity of s-ECSA-Abs (Table 2) suggests that they are useful as new diagnostic markers for esophageal SCC not only by themselves but also in combination with other conventional tumor markers.

Conclusions
We identified ECSA-1, -2 and -3 as novel esophageal SCC SEREX antigens, and designated them as the ECSA family including FAM119A. Serum antibodies against ECSA proteins or a synthetic peptide with a conserved amino acid sequence among the ECSA family members showed a sensitivity higher than 15% and a specificity higher than 98% for patients with esophageal SCC. These results suggest that they are useful as new diagnostic markers for esophageal SCC.

Methods
Human esophageal squamous cell carcinoma cDNA libraries
Sera were collected from patients after they had given written informed consent. This study was approved by
the Local Ethical Review Board of the Chiba University, Graduate School of Medicine. Recombinant DNA work was performed with official permission of the Chiba University, Graduate School of Medicine, in accordance with the rules of the government of Japan. The human esophageal SCC cell line, T.Tn [29,30], was established by the Department of Clinical Molecular Biology, Chiba University, Graduate School of Medicine. Total RNA was prepared from T.Tn cells by the acid guanidine thiocyanate-phenol-chloroform method [31] and purified.

Figure 7 Expression of ECSA family mRNAs in normal and esophageal SCC tissues. The expressions of ECSA-1 (a), ECSA-2 (b), ECSA-3 (c), HCA25a (d), FAM119A (e) and GOSR1 (f) mRNA were examined by RT-PCR in specimens of normal and esophageal SCC tissues resected from patients 1 to 12 (#1 - #12). Each value was normalized with that of GAPDH, and the averages of three experiments are shown. The error bars represent SD (n = 3, t test). Asterisks indicate a significant increase in carcinoma tissues as compared to normal tissues. (*, p < 0.05; **, p < 0.01).
by binding to poly(A)+RNA using Oligotex-dT30 (Super) mRNA Purification Kit (Takara Biochemicals, Kyoto, Japan) according to the manufacturer’s instructions. cDNA was ligated into the EcoRI-XhoI site of the λZAP II phage. The original library size was 1.8 × 10⁶.

Patients and healthy donor sera
Sera were obtained from 146 patients with esophageal SCC and 118 healthy donors. The patients with esophageal SCC included 129 men (89%) and 17 women (11%), with a median age of 65 years (range 44 to 82 years). Before starting treatment, the 146 cancer patients were classified according to the Tumor Node Metastasis/Union Internationale Contre le Cancer (TNM/UIICC) classification system [32] as follows: stage I (n = 32), stage II (n = 29), stage III (n = 42), and stage IV (n = 43). Of the SCC patients, 57 underwent R0 resection with extended lymph node dissection and 89 received definitive chemo-radiation therapy. After treatment, they were followed with clinical examinations and imaging studies on a regular basis until death or until the end of March 2007, whichever occurred first. The mean follow-up time for survivors was 30 months. Each serum sample was centrifuged at 3,000 × g for 5 min, and then the supernatant was stored at -80°C until use. Repeated thawing and freezing of samples were avoided.

Immunological screening of the esophageal carcinoma cell antigens by SEREX
Esophageal carcinoma antigens were screened by the SEREX method previously published by Sahin et al. [10]. E. coli XL1-Blue MRF’ was infected with λZAP II phages containing the cDNA library, and the expression of cDNA was induced by blotting on nitrocellulose membranes (NitroBind, Osmonics Inc., Minnetonka, MN) that had been pretreated for 30 min with 10 mM iso-propl β-D-thiogalactoside (IPTG; Wako Pure Chemicals, Osaka, Japan). The membranes were then washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed in 1:2,000-dilated serum with no preabsorption for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5,000-dilated alkaline phosphatase-conjugated Fc fragment-specific goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA). Positive reactions were detected by incubation in color development solution (100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl₂) containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako Pure Chemicals) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phosphate (Wako Pure Chemicals). Positive clones were recloned twice to obtain monoclonality and retested for serum reactivity.

Sequence analysis of identified antigens
Monoclonalized phage cDNA clones were converted to pBluescript phagemids by in vivo excision using ExAssist helper phage (Stratagene, La Jolla, CA). Plasmid DNA was obtained from an E. coli SOLR strain transformed by the phagemid. The cDNA inserts were sequenced by the dideoxy chain termination method using the DNA Sequencing kit BigDye™ Terminator (Applied Biosystems, Foster City, CA) and ABI PRISM 3700 DNA Analyzer (Applied Biosystems). Sequences were analyzed for homology with public databases of known genes and proteins using NCBI-BLAST.

Western blotting analysis
A total of 40 patients were analyzed by Western blot analysis. E. coli JM109 cells, which contained cDNA clones recombined in pBluescript II, were cultured with or without 1 mM IPTG for 2.5 h. Cells were then washed with phosphate-buffered saline (PBS) and lysed by incubation at 100°C for 3 min in SDS sample buffer [33]. E.coli lysate was then subjected to SDS-PAGE followed by Western blotting using sera of patients or healthy donors as described previously [16,18,19].

Purification of recombinant ECSA proteins
The cDNA insert of ECSA incorporated in pBluescript was cleaved by EcoRI and XhoI, and recombined in pGEX-4T-3 (Amersham Biosciences, Piscataway, NJ). E. coli JM109 cells containing pGEX-4T-3-ECSA or control pGEX-4T-3 were cultured in 200 ml of Luria broth (LB) and treated with 0.1 mM IPTG for 2.5 h. Cells were harvested, washed with PBS and lysed by sonication in

![Figure 8](image-url) Immunochemistry staining of formalin-fixed paraffin-embedded esophageal carcinoma tissues using pan-ECSA mAb. Original magnifications, ×100.
10% Triton X-100, 50 mM Tris-HCl (pH 8.0), 1 mM ethylenediaminetetraacetic acid (EDTA) and 1 mM dithiothreitol (DTT). The lysate was then centrifuged at 10,000 × g for 30 min at 4°C. Glutathione-S-transferase (GST) in the supernatant was directly purified by glutathione-Sepharose (Amersham Biosciences). The purified proteins were concentrated by Apollo centrifugal concentrators (Orbital Biosciences, Topsfield, MA).

Enzyme-linked immunosorbent assay (ELISA)
A total of 72 patients were analyzed by ELISA. Fifty μl of antigens (GST or GST-ECSA) diluted to 10 μg protein/ml in PBS were added to the wells of a microtiter plate, and incubated at room temperature overnight. The plate was washed four times with 0.1% Tween-20 in PBS (PBS-T) and then blocked with 10% fetal bovine serum in PBS (PBS-FBS). The plate was incubated at room temperature for 1 h and washed four times with PBS-T. Fifty μl of the respective sera diluted 1/100 in PBS-FBS were added to the wells and incubated for 1 h. The wells were washed with PBS-T four times, and the bound IgG antibodies were detected by incubation with horseradish peroxidase-conjugated anti-human IgG antibody (Jackson ImmunoResearch Laboratories) for 1 h, followed by washing and the addition of 100 μl of a peroxidase substrate (o-phenylenediamine, 0.4 mg/ml) in citrate-phosphate buffer, pH 5.0, containing 0.02% (v/v) H2O2. The reaction was stopped with 30 μl of 4 M H2SO4. The absorbance at 490 nm was determined with a microplate reader (Emax, Molecular Devices, Sunnyvale, CA).

For sandwich ELISA, micro-titer plates were coated overnight with 50 μl of 10 μg/ml of streptavidin (Wako Pure Chemicals) in 0.05 M carbonate/bicarbonate buffer (pH 9.6). Plates were blocked with 150 μl of PBS-FBS for 1 h, washed four times with PBS-T and incubated overnight with 50 μl of purified biotinylated synthetic peptides (10 μg/ml) in PBS-T. The plate was then washed four times with PBS-T, and 50 μl of serum diluted 1/100 in PBS-FBS were added to each well.

Reverse transcription-PCR (RT-PCR)
Total cellular RNA was isolated from the tumor tissues using FastPure RNA Kit (Takara Bio). Reverse transcription was carried out with oligo(dT)20 primer using the ThermoScript RT-PCR System (Invitrogen, Carlsbad, CA), according to the manufacturer’s instructions. The presence of ECSA transcripts was established via quantitative realtime RT-PCR using the following primers and probes (Universal Probe Library; Roche, Basel, Switzerland).

ECSA-1 sense: 5’-TAAGGGCCGTGCAAGATG-3’
ECSA-1 antisense: 5’-TAGGGAGTGGTGACT CCTA-3’
ECSA-1 probe: #8
ECSA-2 sense: 5’-GAGACTTTTCATTGTTCTG-CACT-3’
ECSA-2 antisense: 5’-GGGGGTAAAGTCA-GATCA-3’
ECSA-2 probe: #6
ECSA-3 sense: 5’-GACATGGAGACTTTT-CATTITG-3’
ECSA-3 antisense: 5’-CTGTGGGATTTGGTGT-GATA-3’
ECSA-3 probe: #29
FAM119A sense: 5’-AATGCAGTTTTCTCC-CAAGC-3’
FAM119A antisense: 5’-TTTTATGCTACCC-TATGCCTTG-3’
FAM119A probe: #38
GOSR1 sense: 5’-TGACGTGGAGCAAAAGAT-3’
GOSR1 antisense: 5’-GTCGAGCCTGTTCTCG AGA-3’
GOSR1 probe: #48
BBS5 sense: 5’-CAGTCCCATATTTGGAGTTGATT-3’
BBS5 antisense: 5’-TCGACTGTCAGCCTCGAG-3’
BBS5 probe: #45
HCA25a sense: 5’-CTGTTCCTGAAATCTGTTTC CTCTT-3’
HCA25a antisense: 5’-AGAGGGAGACCGTG- GAAG-3’
HCA25a probe: #52
hGAPDH sense: 5’-AGCCACATCGCTAGACACA-3’
hGAPDH antisense: 5’-GCCCAATACGACAAA TCC-3’
hGAPDH probe: #60

PCR was performed using Fast Start Taq Man probe Master (Roche) and ABI PRISM 7000 Sequence Detection System (Applied Biosystems LLC) as follows: an initial denaturation step at 95°C for 2 min, followed by 55 cycles of denaturation at 95°C for 15 sec and annealing/extension at 60°C for 30 sec. The ΔΔCT mean and SD were calculated and normalized to the GAPDH value.

The presence of ECSA transcripts was also examined by standard PCR using the following primer pairs: ECSA-3 sense, 5’-GACATGGAGACTTTTCACTTTTCTC-3’; ECSA-3 antisense, 5’-CTGTGGGATTTGGTGAT GATA-3’; β-actin sense, 5’-GGATCACGCAAGCAGGAGTATG-3’; β-actin antisense, 5’-GAGAGTGAGGGGTGCTTTTAG-3’. PCR was performed using KOD-Plus-DNA polymerase (Toyobo, Osaka, Japan) as follows: an initial denaturation step at 94°C for 2 min, followed by 36 cycles for ECSA-3, or 28 cycles for β-actin, of denaturation at 94°C for 15 sec, annealing at 60°C for 30 sec, and extension at 68°C for 30 sec, with a
final extension of 5 min at 68°C using Takara PCR Thermal Cycler SP (Takara Bio, Otsu, Japan).

Preparation of HCA25a antibody
Monoclonal anti-HCA25a antibody was developed by immunizing mice with recombinant HCA25a protein. The antibody obtained from the culture medium of the hybridomas reacted with ECSA-1, -2 and -3, and was designated as pan-ECSA mAb.

Immunohistochemical staining for HCA25a protein
Paraffin-embedded esophageal SCC tumor tissues were cut and dewaxed through alcohol/xylene gradient solutions. After antigen retrieval by incubation at 95°C for 40 min in 10 mM citrate buffer (pH 6.0), endogenous peroxidase was blocked with 3% hydrogen peroxide in methanol for 15 min. After blocking with 5% non-fat dry milk in PBS for 30 min, sections were incubated for 1 h with pan-ECSA mAb diluted at 1:200. Parallel sections were incubated with 5% non-fat dry milk as negative controls. All sections were washed three times with wash buffer (DAKO Corporation, CA) for 5 min each. For linking, all sections were incubated with biotinylated anti-mouse IgG, and reacted with streptavidin-conjugated horseradish peroxidase reagent (DAKO LSAB® +HRP system). Finally, the reaction was visualized with a chromogen, diaminobenzidine, in 3% hydrogen peroxidase. Sections were then counterstained with hematoxylin, dehydrated and mounted.

Statistical Analyses
Fisher’s exact (two-sided) probability test and the Mann-Whitney U test were used to determine the significance of the differences between two groups. The survival probabilities were calculated using the product-limit method of Kaplan and Meier, considering all deaths. Survival differences between groups were determined using the log-rank test. All statistical analyses were carried out using the Stat View 5.0J program for Windows (SAS Institute Inc., Cary, NC). P values lower than 0.05 were considered statistically significant.

Additional material

Additional file 1: Nucleotide and amino acid sequences of ECSA-1, -2 and -3. Coding regions of the nucleotide sequences are underlined.

Additional file 2: Purification of recombinant ECSA-2 protein using glutathione-Sepharose. cDNA of ECSA-2 was recombined into pGEX-4T, which produced the GST-ECSA-2 fusion protein after treatment with IPTG. The fusion protein was affinity-purified by glutathione-Sepharose. 1, total extract; 2, supernatant fraction after lysis with Triton X-100 followed by centrifugation; 3, precipitate fraction after lysis with Triton X-100 followed by centrifugation; 4, flow-through/unbound fraction; 5, glutathione-eluted fraction. Coomassie-stained SDS-polyacrylamide gel is shown.

List of abbreviations used
EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl β-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse transcription-polymerase chain reaction; SCC: squamous cell carcinoma; SEREX: serological identification of antigens by recombinant cDNA expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.

Acknowledgements
This work was supported by 21st Century COE (Center of Excellence) Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Grant Sponsor: Grant-in-Aid for Scientific Research (#17591370 and #16390372) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

We thank Ms. Masae Suzuki and Aiko Kimura for their helpful technical assistance.

Author details
1Department of Biochemistry and Genetics, Chiba University, Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan. 2Department of Frontier Surgery, Chiba University, Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan. 3Department of Surgery, School of Medicine, Toho University, Ota-ku, Tokyo 143-8541, Japan. 4Product Development Department, Medical & Biological Laboratories Co., Ltd., Ina, Nagano 396-0002, Japan. 5Department of Bioinformatics, Chiba University, Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan. 6Department of Molecular Diagnosis, Chiba University, Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan. 7Gastroenterological Center, San-Ai Memorial Hospital, Chuo-ku, Chiba 260-0806, Japan.

Authors’ contributions
THi, HS, and MT designed the overall research plan. AK, TS, MK, KNF, and MY performed SEREX screening and carried out ELISA, SK, THa, and AM prepared antigen proteins, YT designed the antigen peptides, and FN, TO, TN, HM prepared tissue samples and carried out expression analysis. All authors read and approved the final manuscript.

Competing interests
Takaki Hiwasa and Hideaki Shimada have received research support from Medical & Biological Laboratories Co., Ltd. in 2005 - 2007.

Received: 26 November 2010 Accepted: 23 June 2011 Published: 23 June 2011

References
1. Isono K, Ochiai T: Recent advances of treatment of cancer of the esophagus (review). Ann Cancer Res Therapy 1992, 1:9-16.
2. Shimada H, Nabeia Y, Okaizumi S, Matsubara H, Shiratori T, Gunji Y, Kobayashi S, Hayashi H, Ochiai T: Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 2003, 133:486-494.
3. Daly JM, Karsell LH, Menck HR: National cancer data base report on esophageal carcinoma. Cancer 1996, 78:1820-1828.
4. Shimada H, Kitabayashi H, Nabeia Y, Okaizumi S, Matsubara H, Funami Y, Miyazawa Y, Shiratori T, Uno T, Ino H, Ochiai T: Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 2003, 133:244-51.
5. Kim YH, Ajani JA, Ota DM, Lynch P, Roth JA: Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer 1995, 75:451-456.
6. Munck-Wikland E, Kuylenstierna R, Wahren B, Lindholm J, Haglund S. Tumor markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Pretreatment screening. Cancer 1988, 62:2281-2286.
7. McKnight A, Manneil A, Sherling I. The role of carbohydrate antigen 19-9 as a tumour marker of oesophageal carcinoma. Br J Cancer 1989, 60:249-251.
8. Foley EJ. Attempts to induce immunity against mammary adenocarcinoma in intrbred mice. Cancer Res 1953, 13:578-580.
9. Prehn RT, Mann JM. Immunity to methylcholangthrene-induced sarcomas. J Natl Cancer Inst 1957, 18:769-778.
10. Sahin U, Tureo O, Schmitt H, Cochetlouis B, Johannes T, Schmids R, Sterner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995, 92:11810-11813.
11. Cancer immune database. [http://www2.lirc.org/CancerImmuneDB/].
12. Chet YT, Scanlan MJ, Sahin U, Tureo O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997, 94:1914-1918.
13. Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funarni Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 2000, 89:1677-1683.
14. Shimada H, Nakajima K, Ochiai T, Koide Y, Okazumi S, Matsubara H, Takeda A, Miyazawa Y, Arima M, Isomo K. Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: correlation with clinicopathological features and tumor markers. Oncol Rep 1998, 5:871-874.
15. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funarni Y, Shiratori T, Hayashi H, Takeda A, Ochiai T. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 2002, 132:41-47.
16. Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiva N, Okazumi S, Matsubara H, Nomura F, Takiguchi M, Hwasa T. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer 2004, 112:1029-1035.
17. Shimada H, Nakashima K, Ochiai T, Nabeya Y, Takiguchi M, Nomura F, Hwasa T. Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol 2005, 26:77-86.
18. Kuboshima M, Shimada H, Liu TL, Nakashima K, Nomura F, Takiguchi M, Hwasa T, Ochiai T. Identification of a novel SEREX antigen, SLC2A1/Glut1, in esophageal squamous cell carcinoma. Int J Oncol 2006, 28:463-468.
19. Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hwasa T, Ochiai T. Presence of serum TRIM21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci 2006, 97:389-396.
20. Hwasa T, Shimada H, Ochiai T, Takiguchi M. Serological identification of antigens by recombinant cDNA expression cloning (SEREX) using antibodies from patients with esophageal squamous cell carcinoma, in Moleculeomics and Thereafter. Edited by: Hwasa T, Keralia, India: Research Signpost, 2006:99-117.
21. Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H, Nomura F, Takiguchi M, Ochiai T, Hwasa T. Serum anti-myogegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol 2007, 30:97-103.
22. Shiratori T, Shimada H, Kagaya A, Kuboshima M, Nabeya Y, Machida T, Goto K, Takiguchi M, Ochiai T, Hwasa T. Sensitization against anticancer drugs by transfection with UBE2I variant gene into ras-NH3T3 mouse fibroblasts. Anticancer Res 2007, 27:3227-3234.
23. Hwasa T, Shimada H, Kuboshima M, Shiratori T, Kagaya A, Nabeya Y, Sugano S, Ochiai T, Matsubara H, Takiguchi M. Decrease in chemosensitivity against anticancer drugs by an esophageal squamous cell carcinoma SEREX antigen, AISEC, Int J Oncol 2009, 34:641-646.
24. Shimada H, Kagaya A, Shiratori T, Nomura F, Takiguchi M, Matsubara H, Hwasa T. Detection of anti-CUEC-23 antibodies in serum of patients with esophageal squamous cell carcinoma—possible new serum marker for esophageal cancer. J Gastroenterol 2009, 44:691-696.
25. Shimada H, Shiratori T, Yasuoka M, Kagaya A, Kuboshima M, Nomura F, Takiguchi M, Ochiai T, Matsubara H, Hwasa T. Identification of Makorin 1 as a novel SEREX antigen of esophageal squamous cell carcinoma. BMC Cancer 2009, 9:232.
26. Tureci O, Sahin U, Zwick C, Koslowski M, Setz G, Pfreundschuh M. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci USA 1996, 93:5211-5216.
27. Nesterova M, Johnson N, Kneidle C, Cho-Chung YS. Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 2006, 1762:398-403.
28. Kasid U, Pfeifer A, Brennan T, Beckett M, Weichselbaum RR, Dritschilo A, Mark GE. Effect of antisense c-raf-1 on tumorigenicy and radiation sensitivity of a human squamous carcinoma. Science 1989, 243:1354-1356.
29. Takahashi K, Kanazawa H, Chan H, Hosono T, Takahara M, Sato K. A case of esophageal carcinoma metastatic to the mandible and characterization of two cell lines (T.T. and T.Tn). Jpn J Oral Maxillofac Surg 1990, 36:307-316.
30. Shimada H, Shimizu T, Ochiai T, Liu TL, Sashiyama H, Nakamura A, Matsubara H, Gunji Y, Kobayashi S, Tagawa M, Sakoyma S, Hwasa T. Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surg Today 2001, 31:597-604.
31. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
32. Sabir LH, Wittkendin CH, Eds: UICC TNM Classification of malignant tumors. New York, John Wiley & Sons, 6 2000.